HIV protease inhibitors
US9994587B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Mar 2, 2015 |
| Grant date | Jun 12, 2018 |
| Priority date | — |
| Expiry date | Mar 2, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to 2,6-morpholine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein Z1, Z2, V1, V2, V3, R6, R6A, and X are defined herein. The invention also relates to methods of using the 2,6-morpholine derivatives of the invention for the inhibition of HV protease, the inhibition of HV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.